+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free

Hepatitis B Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Pre Book Price: $ 5216

Original Price: $ 5795

Hepatitis B is a life threatening liver infection caused by hepatitis B virus. Adults who get affected by hepatitis B virus for a short time and then get cured is known as acute hepatitis B. Infection that lasts for a long time is known as chronic hepatitis B. Vaccine is the most preferred choice of doctors and physicians to protect people from the disease. The vaccine prevents the infection and stops development of liver cancer and chronic disease caused by hepatitis B. It can cause a long term infection and put people at high risk of liver cancer and cirrhosis that may lead to death. Globally, hepatitis B is one of the major health problems that spreads by mucosal or percutaneous exposure as well as through menstrual, seminal, saliva, and vaginal fluids. Hepatitis B can occur due to sexual transmission, by having contact with sex workers and sex with multiple partners. Transmission of disease may also occur due to reuse of syringes and needles both among persons who inject drugs and in health care settings. Moreover, it may occur during surgical, medical, and dental procedures, and use of razors that are contaminated with infected blood. Infants and young children mostly get chronic hepatitis B.

Hepatitis B Therapeutics Market: Dynamics

Limited access to treatment and diagnosis of hepatitis B in many resource constrained settings and increasing prevalence of hepatitis B infections are likely to drive the global hepatitis B therapeutics market during the forecast period. Rising awareness and increasing affordability are some of the key factors that will increase the rate of diagnosis before a person having advanced liver disease. According to the World Health Organization (WHO), infection of chronic hepatitis B is most common in infants. Rising incidence of hepatitis B infections is a major driver of the market. Less availability of antibiotics in the market and effectiveness of antivirals against hepatitis B infections is likely to propel the market during the forecast period. Prevalence of hepatitis B is increasing steadily across the globe. Medications and treatment options are highly expensive. These are the major drivers of the hepatitis B therapeutics market.

Hepatitis B Therapeutics Market: Segmentation

Based on therapy, the global hepatitis B therapeutics market has been segmented into:

  • Chemo Therapy
  • Immunosuppressant Therapy
  • Nucleoside Analogue

In terms of product type, the global hepatitis B therapeutics market has been segmented into:

  • Hepatitis B Vaccine
  • Anti-viral Drugs
    • Tenofovir
    • Entecavir

Based on distribution channel, the global hepatitis B therapeutics market has been segmented into:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Hepatitis B Therapeutics Market: Region-wise Outlook

In terms of region, the hepatitis B therapeutics market has been segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominated the hepatitis B therapeutics market owing to the high awareness levels, availability of improved infrastructure, and favorable government initiatives relating to the promotion of hepatitis B therapeutics. Europe is the second largest market for hepatitis B therapeutics driven by rising geriatric population, high rates of chronic infections in Central and Eastern Europe. Prevalence of hepatitis B is the highest in Middle East & Africa where adult population is chronically infected. According to the WHO, it is estimated that 2% to 5% of general population is affected chronically in Asia Pacific. Most people with liver cancer die within diagnosis as there are limited treatment options.

Hepatitis B Therapeutics Market: Key Players                

Major players operating in the global hepatitis B therapeutics market are GlaxoSmithKline plc, Bristol-Myers Squibb, Novira Therapeutics, Johnson & Johnson, Abivax SA, F. Hoffmann- La Roche, Novartis AG, and Merck & Co. The increasing competition among key players is likely to drive the global hepatitis B therapeutics market during the forecast period. 

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   
     

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.


Note : All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Transparency Market Research.


To receive discount, please click on the button below.

Please click on the button below to customize this report.

 
 
Back To Top